24 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Segmental Artery Coil-Embolization’: A Randomized Controlled Multicentre Trial (PAPA-ARTIS)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in ...
Voir le projet
26
Participants partenaires
TERMINÉ
Bile acid, immune-metabolism, lipid and glucose homeostasis (ImmunoBile)
Date du début: 1 sept. 2016, Date de fin: 31 août 2021,
The role of chronic inflammation in obesity, metabolic and cardiovascular diseases is increasingly recognized. Bile acids (BA), synthesized in the liver and modified by the gut flora, facilitate lipid absorption in the intestine. BA modulate lipid and glucose homeostasis by activating the nuclear receptor FXR and the GPCR TGR5. Intriguingly, peripheral BA concentrations are elevated in type 2 diab...
Voir le projet
2
Participants partenaires
TERMINÉ
TRUst-Enhancing certified Solutions for SEcurity and protection of Citizens’ rights in digital Europe (TRUESSEC.EU)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2018,
TRUESSEC.EU is a CSA on certification and labelling of trustworthiness properties from a multidisciplinary SSH-ICT perspective and with emphasis on human rights.The current complexity of ICT products and services makes it difficult to appraise their trustworthiness. Thus, certification becomes a must to restore transparency and trust. TRUESSEC.EU aims at exploring the situation, the barriers, and ...
Voir le projet
8
Participants partenaires
TERMINÉ
Unravelling the mode of action of mucosal adjuvants (MucoVac)
Date du début: 1 sept. 2016, Date de fin: 31 août 2018,
The development of new vaccines against infectious diseases is a major worldwide public health objective. Despite the availability of antimicrobial therapies, vaccines still constitute the most effective means of controlling infections. Adjuvants are crucial for increasing the onset, magnitude, diversity and memory of immune responses to vaccines. Whereas a range of adjuvants is available for conv...
Voir le projet
2
Participants partenaires
TERMINÉ
Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,
Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptabl...
Voir le projet
17
Participants partenaires
TERMINÉ
Genetics and epigenetics of Type 2 Diabetes physiology (GEPIDIAB)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
"Failure to elucidate Type 2 Diabetes (T2D) physiology frustrates efforts to improve therapeutics. Although GWAS has identified 40 T2D genes, mostly expressed in pancreatic beta-cells, this explains no more than 10% of T2D inheritance. Up to 5% of T2D patients have dominantly inherited maturity-onset diabetes of the young (MODY), characterized by beta-cell dysfunction. Elucidating the genetics of ...
Voir le projet
3
Participants partenaires
TERMINÉ
Universal Flu Vaccine (UNIVACFLU)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.The aim is to ...
Voir le projet
8
Participants partenaires
TERMINÉ
Higher education student and staff mobility project
Date du début: 1 juin 2016, Date de fin: 30 sept. 2017,
This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Voir le projet
1
Participant partenaire
TERMINÉ
Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EURHYTHDIA)
Date du début: 1 oct. 2011, Date de fin: 30 juin 2017,
Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours, as technical and economical de-mands fuel the necessity to work outside usual working hours. Recent studies show that al-tered light exposure, shifted exercise patterns and untimely food intake following extended active periods into the night di...
Voir le projet
17
Participants partenaires
TERMINÉ
ROLE OF THE TANYCYTIC BARRIER AT THE BLOOD-HYPOTHALAMUS INTERFACE DURING METABOLIC DISORDER DEVELOPMENT (GLIODIABESITY)
Date du début: 1 juil. 2015, Date de fin: 30 juin 2017,
Metabolic disorders such as obesity and diabetes are age-related diseases, and lead cause of death in Europe. Adiposity signals such as leptin and insulin, whose circulating levels are in proportion to body fat, convey metabolic information to neural networks that regulate energy homeostasis in the hypothalamus. In leptin-deficient humans and mice, leptin administration effectively reduces hyperph...
Voir le projet
2
Participants partenaires
TERMINÉ
Higher education student and staff mobility project
Date du début: 1 juin 2015, Date de fin: 31 mai 2017,
This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Voir le projet
1
Participant partenaire
TERMINÉ
Regulation and consequences of LRRK2 phosphorylation,a path to Parkinson’s disease therapy and diagnostics (RECOLOR)
Date du début: 1 juin 2015, Date de fin: 31 mai 2017,
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, currently incurable. Studies in the PD field show that leucine-rich repeat kinase 2 (LRRK2) is both a major player in PD pathogenesis and a promising PD therapeutic target. LRRK2 functions in health and disease are not defined; however the applicant and others have shown that LRRK2 phosphorylation is the key to unders...
Voir le projet
1
Participant partenaire
TERMINÉ
Development of biophotonic device based on flexible light emitting textile dedicated to the monitoring and treatment for dermatologic diseases and carcinoma (PHOS-ISTOS)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2016,
The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the...
Voir le projet
12
Participants partenaires
TERMINÉ
Value Analysis of Local Utilities of Enterprises from Social sector (VALUES)
Date du début: 22 févr. 2012, Date de fin: 21 févr. 2016,
The research program focuses on a central theme relating governance and regulation of the sector of the social economy in a territorial context. This project is based on Vaesken and Zafiropoulou model centered to social innovation resulting from the articulation between modes of governance and modes of regulation.The program treats three specific research orientations of social policies and local ...
Voir le projet
4
Participants partenaires
TERMINÉ
Understanding food-gut-brain mechanisms across the lifespan in the regulation of hunger and satiety for health (Full4Health)
Date du début: 1 févr. 2011, Date de fin: 31 janv. 2016,
Full4Health is a multidisciplinary European collaboration of internationally renowned laboratories investigating the mechanisms of hunger, satiety and feeding behaviour, effects of dietary components and food structure on these processes, and their possible exploitation in addressing obesity, chronic disease and under-nutrition. The proposal integrates investigation of both human volunteers (dieta...
Voir le projet
16
Participants partenaires
TERMINÉ
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef...
Voir le projet
38
Participants partenaires
TERMINÉ
Improving medical treatment adherence : taking into account patients' perception of uncertainty in the causal relationship between their adherence behaviour and their health condition (IMPROVINGADHERENCE)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2015,
Non-adherence, defined as the discrepancy between patients' behaviour and medical prescriptions, is a massive public health issue, the consequences of which are serious. Nearly half of the patients who have a chronic disease do not take their treatment as prescribed. In order to improve our understanding of this phenomenon and to remedy it, the proposed research will examine following hypothesis :...
Voir le projet
1
Participant partenaire
TERMINÉ
Higher education student and staff mobility project
Date du début: 1 juin 2014, Date de fin: 30 sept. 2015,
This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Voir le projet
1
Participant partenaire
TERMINÉ
Beta Cell Therapy in Diabetes (BETACELLTHERAPY)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage...
Voir le projet
18
Participants partenaires
TERMINÉ
COntinuous Multi-parametric and Multi-layered analysis Of DIabetes TYpe 1 & 2 (Commodity12)
Date du début: 1 oct. 2011, Date de fin: 30 juin 2015,
In COMMODITY12 we will build a multi-layered multi-parametric infrastructure for continuous monitoring of diabetes type 1 and 2. The COMMODITY12 system will exploit multi-parametric data to provide healthcare workers and patients, with clinical indicators for the treatment of diabetes type 1 and 2. COMMODITY12 will focus on the interaction between diabetes and cardiovascular diseases. To address...
Voir le projet
11
Participants partenaires
TERMINÉ
CIVIL SOCIETY ORGANISATIONS IN DESIGNING RESEARCH GOVERNANCE (CONSIDER)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2015,
Broader stakeholder engagement in technical and scientific research is desirable for a variety of reasons. Civil Society Organisations (CSOs) can be optimal actors to realise the promise of participative research governance. Despite much activity to stimulate and implement CSO participation in research, there is no agreement on how to evaluate the success of participation.CONSIDER will undertake c...
Voir le projet
8
Participants partenaires
TERMINÉ
"Fungi in the setting of inflammation, allergy and autoimmune diseases:Translating basic science into clinical practices" (ALLFUN)
Date du début: 1 déc. 2010, Date de fin: 31 mai 2014,
"The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to immune homeostasis and its dysregulation leading to allergy and inflammatory diseases. Breakthroughs in understanding how mucosal homeostasis is established, maintained or disrupted in the presence of fungi should be sources of new therapeutic targets and drugs...
Voir le projet
14
Participants partenaires
TERMINÉ
PATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION (PSIP)
Date du début: 1 janv. 2008, Date de fin: 31 juil. 2011,
Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients' safety and originate considerable extra hospital costs.Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recomm...
Voir le projet
13
Participants partenaires
TERMINÉ
Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets (MEMOSAD)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease (AD). Insoluble aggregates of the two proteins provide the pathological hallmarks of this incurable brain disorder. Early stage AD is characterized by a remarkably pure impairment of declarative memory a...
Voir le projet